Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.645 USD | +0.92% | -1.48% | -43.51% |
Apr. 11 | BTIG Starts Carisma Therapeutics With Buy Rating, $6 Price Target | MT |
Apr. 02 | HC Wainwright Adjusts Price Target on Carisma Therapeutics to $9 From $11, Maintains Buy Rating | MT |
Financials (USD)
Sales 2024 * | 16.93M | Sales 2025 * | 13.83M | Capitalization | 67.71M |
---|---|---|---|---|---|
Net income 2024 * | -58M | Net income 2025 * | -69M | EV / Sales 2024 * | 4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.9 x |
P/E ratio 2024 * |
-1.26
x | P/E ratio 2025 * |
-1.22
x | Employees | 107 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 67.27% |
1 day | -2.40% | ||
1 week | -4.12% | ||
1 month | -28.19% | ||
3 months | -22.38% | ||
6 months | -45.67% | ||
Current year | -44.37% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 34 | 15-12-31 | |
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Richard Morris
DFI | Director of Finance/CFO | 51 | 21-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Steven Kelly
CEO | Chief Executive Officer | 59 | 18-01-31 |
Sanford Zweifach
CHM | Chairman | 68 | 21-10-31 |
Director/Board Member | 66 | 22-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.01% | 0 M€ | 0.00% | - | |
0.00% | 34 M€ | +1.51% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-01 | 1.655 | +1.54% | 5 259 |
24-04-30 | 1.63 | -2.40% | 91,241 |
24-04-29 | 1.67 | +1.83% | 118,071 |
24-04-26 | 1.64 | 0.00% | 54,732 |
24-04-25 | 1.64 | -2.38% | 112,570 |
Delayed Quote Nasdaq, April 30, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.37% | 67.71M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.95% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- CARM Stock